MedPath
NMPA Approval

Hydrotalcite Suspension

国药准字H20243135

February 6, 2024

Drug Information

铝碳酸镁混悬液

口服混悬剂

10ml:1g

化学药品

February 6, 2024

Company Information

Applicant Company

四川省成都市新都区大丰街道蓉北路一段138号

Manufacturing Company

四川省成都市双流区西南航空港经济开发区腾飞二路319号

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

铝碳酸镁混悬液 - NMPA 批准文号 | MedPath